Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hepatitis probably caused by exifone (Adlone)].

D Larrey1, P Biclet, A Razafimahaleo

  • 1Unité de Recherches de Physiopathologie Hépatique (INSERM U-24), Hôpital Beaujon, Clichy, Paris.

Gastroenterologie Clinique Et Biologique
|April 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beclin 1 mRNA strongly correlates with Bcl-XLmRNA expression in human hepatocellular carcinoma.

Cancer investigation·2007
Same author

Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.

Journal of viral hepatitis·2006
Same author

Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma.

Histopathology·2006
Same author

Multiple mixed adenoma-focal nodular hyperplasia of the liver associated with spontaneous intrahepatic porto-systemic shunt: a new type of vascular malformation associated with the multiple focal nodular hyperplasia syndrome?

Histopathology·2006
Same author

Interferon-alpha suppresses liver cell proliferation in patients with chronic hepatitis C virus infection.

Journal of viral hepatitis·2005
Same author

Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis.

Journal of viral hepatitis·2005

Exifone, a drug for cognitive deficiencies, caused jaundice in two patients. Liver damage resolved after discontinuing the medication, indicating a potential adverse drug reaction.

Area of Science:

  • Hepatology
  • Clinical Pharmacology
  • Geriatrics

Background:

  • Exifone was introduced in France in April 1988 for treating age-related cognitive decline.
  • Cognitive deficiencies in the elderly represent a significant public health concern.
  • Pharmacovigilance is crucial for identifying adverse drug reactions in geriatric populations.

Observation:

  • Two patients developed jaundice after 2 and 5 months of Exifone treatment.
  • Elevated serum aminotransferase levels were observed in both cases.
  • Histological examination revealed centrilobular hepatocyte necrosis and cholestasis.

Findings:

  • The liver lesions included infiltration of necrotic cells with erythrocytes and inflammatory cells.
  • Alterations in the walls of centrilobular veins were noted.

Related Experiment Videos

  • Discontinuation of Exifone led to rapid resolution of jaundice and complete recovery within 6-12 weeks.

    • Implications:

    • Exifone may be associated with drug-induced liver injury (DILI).
    • This highlights the importance of monitoring liver function in patients taking Exifone.
    • Further investigation into the hepatotoxicity of Exifone is warranted.